Description: Adhera Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of proprietary drug therapeutics primarily for hypertension, arthritis, pain, and oncology in the United States, Europe, and internationally. The company offers Prestalia, a single-pill fixed dose combination (FDC) of perindopril argenine, an angiotensin-converting-enzyme inhibitor; and amlodipine besylate, a calcium channel blocker for the treatment of hypertension. Its clinical development programs include IT-102 and IT-103, a celecoxib program drug candidates for the treatment of combined arthritis pain/hypertension and the treatment of pain requiring a high dose of celecoxib; CEQ508, an oral delivery of small interfering RNA against beta-catenin, combined with IT-102 to suppress polyps in the precancerous syndrome and orphan indication familial adenomatous polyposis; and CEQ508 combined with IT-103 to treat colorectal cancer. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Durham, North Carolina.
Home Page: adherathera.com
8000 Innovation Parkway
Baton Rouge,
LA
70820
United States
Phone:
919 518 3748
Officers
| Name | Title |
|---|---|
| Dr. Zahed Subhan B.S., BS, L.L.B., LLB (Law), M.B.A., M.S., MBA, MS | CEO, Chief Scientific Officer & Chairman |
| Mr. Andrew Albert Kucharchuk M.B.A. | Vice Chairman, COO, Acting CFO & Chief Bus. Officer |
Exchange: OTCQB
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 8.2348 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |